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Serum amyloid A (SAA) is one of the acute phase proteins synthesized in hepatocytes and secreted by various inflammation or
infectious stimuli. We investigated the clinical implication of measuring SAA in patients with antineutrophil cytoplasmic
antibody- (ANCA-) associated vasculitis (AAV). Seventy-five patients who had been classified as AAV and enrolled in our
prospective observational cohort for AAV patients were included. Clinical and laboratory data were obtained on the day of
blood sampling, and SAA was measured by ELISA kits. Birmingham Vasculitis Activity Score (BVAS) and Short-Form 36-Item
Health Survey (SF-36) were assessed for disease activity and health-related quality-of-life (HRQoL) measures. We stratified
patients into having high BVAS when the BVAS was over the median values, and those with either low SF-36 PCS or low SF-36
MCS were defined as having poor HRQoL. Multivariate logistic regression analysis was conducted to estimate independent
predictors of high BVAS. The relative risk (RR) was analyzed using the contingency tables and the chi-squared test. SAA was
positively correlated with BVAS (r = 0:642) and FFS (r = 0:367) and was inversely correlated with both the SF-36 physical
component summary (r = −0:456) and mental component summary scores (r = −0:394). Furthermore, SAA was significantly
correlated with acute phase reactants ESR (r = 0:611) and CRP (r = 0:629). Patients with high BVAS exhibited significantly
higher SAA than those with low BVAS (1317.1 ng/mL vs. 423.1 ng/mL). In multivariable logistic regression analysis, serum
albumin (odds ratio (OR) 0.132) and SAA > 1173:6 ng/mL (OR 15.132) were independently associated with high BVAS. The
risk of having high BVAS and poor HRQoL in patients with SAA > 1173:6 ng/mL was higher than in those with SAA ≤ 1173:6
ng/mL (RR 3.419 and 1.493). Our results suggest that SAA might be a useful biomarker in assessing disease activity and HRQoL
in AAV.
1. Introduction
Antineutrophil cytoplasmic antibody- (ANCA-) associated
vasculitis (AAV) is a group of the systemic vasculitides affect-
ing small vessels such as microscopic polyangiitis (MPA),
granulomatosis with polyangiitis (GPA), and eosinophilic
granulomatosis with polyangiitis (EGPA), which exhibit nec-
rotizing vasculitis in arterioles, capillaries, and venules [1].
However, heterogeneous clinical phenotypes are present
between the three diseases: MPA primarily provokes rapidly
progressive crescentic glomerulonephritis and diffuse alveo-
lar hemorrhage, whereas GPA mainly forms granulomas
and affects the upper and lower respiratory tracts [1, 2]. By
contrast, EGPA is composed of 3 phases such as allergic,
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eosinophilic, and vasculitis phases and is characterized by
asthma, sinusitis, peripheral eosinophilia, eosinophil infiltra-
tion, and organ damages in lungs and nerves [3].
Birmingham Vasculitis Activity Score (BVAS) has been
improved over the decades, and its 3rd version is now most
commonly used for assessing the disease activity of AAV [4].
Since BVAS covers a wide range of nine systemic categories
with differently weighted scores based on the severity of each
symptom, it has been considered the most reliable tool to
assess AAV activity to date [5]. However, since BVAS includes
not only the cross-sectional clinical features but also the
chronic clinical features such as lung fibrosis and renal dys-
function, there is a difficulty using BVAS as an indicator of
cross-sectional activity or severity of AAV [5]. So far, we have
demonstrated the clinical significance of several AAV activity-
related indices consisting of serum concentrations of endoge-
nous proteins or equations of laboratory data for predicting
the cross-sectional activity of AAV based on BVAS [6, 7].
Although the clinical utility of these indices may not exceed
that of BVAS, owing to the paucity of reliable biomarkers
available, it ismeaningful to search for novel markers that hold
clinical implications in AAV which are expected to possess a
complementary role in assessing AAV activity.
Serum amyloid A (SAA) is one of the typical acute phase
proteins synthesized in hepatocytes and secreted by various
inflammation or infectious stimuli [8, 9]. The production
and secretion of SAA from the liver are accelerated by proin-
flammatory cytokines such as interleukin- (IL-) 1, IL-6,
tumor necrosis factor (TNF), interferon-γ, and transforming
growth factor-β (TGF-β) [10]. Therefore, it could be theoret-
ically assumed that SAA may be closely correlated with the
amount of the inflammatory burden of autoimmune disor-
ders. In this context, previous studies elucidated that SAA
was significantly correlated with the activity of systemic vas-
culitides such as Takayasu arteritis, Behcet’s disease, and
Henoch-Schönlein purpura [11–13]. Furthermore, SAA has
also been reported to be a potential biomarker of different
types of lung disorders and inflammatory environment and
is useful in assessing disease activity of systemic lupus erythe-
matosus [14–16]. However, to the best of our knowledge,
there was no study that reported the association between
SAA and clinical and laboratory features of AAV. Hence, in
this study, we investigated the utility of measuring SAA from
a prospective cohort of AAV patients.
2. Materials and Methods
2.1. Study Population. In this study, we included 75 AAV
patients who had been enrolled in the Severance Hospital
ANCA-associated VasculitidEs (SHAVE) cohort from
November 2016 to May 2019. The SHAVE cohort is a pro-
spective observational cohort of patients with MPA, GPA,
and EGPA, which began in November 2016 in a tertiary
referral center in South Korea. All patients were classified
as AAV at the Division of Rheumatology, Department of
Internal Medicine, Severance Hospital. They all fulfilled the
1990 American College of Rheumatology classification
criteria for EGPA, the 2007 European Medicines Agency
algorithm for AAV and polyarteritis nodosa (the 2007
EMA algorithm), and the 2012 revised International Chapel
Hill Consensus Conference Nomenclature of Vasculitides
[1–3]. Based on the entry requirement of the 2007 EMA algo-
rithm, AAV patients, who were accompanied by chronic
infection including hepatitis B or C virus infection, malig-
nancies, or secondary vasculitis features related to autoim-
mune diseases, were excluded [2]. The ethical permission
regarding the study was approved by the Institutional Review
Board of Severance Hospital (4-2016-0901).
2.2. Clinical and Laboratory Data. Demographic data
included age, gender, and disease duration. The clinical man-
ifestations were counted based on the items of BVAS version
3, and laboratory tests including ANCAs were performed.
Four AAV-specific indices were assessed: the BVAS version
3 for disease activity [5]; the five-factor score (2009) for prog-
nostic evaluation [17]; the Korean version of the Short-Form
36-Item Health Survey (SF-36) for health-related quality-of-
life (HRQoL) [18]; and the vasculitis damage index (VDI) for
organ injury or damage [19]. The BVAS was calculated for all
of the patients by evenly applying BVAS version 3 to unify
the scoring system. On the same day of clinical and labora-
tory data obtainment, whole blood was drawn from each
patient upon consent and was immediately centrifuged to
isolate sera which were then stored at –80°C. SAA was mea-
sured from stored sera with ELISA kits from Invitrogen
(Waltham, MA, USA) according to the manufacturer’s
instruction.
2.3. Definition of High BVAS and Poor HRQoL.We stratified
patients into having high BVAS when the BVAS was over the
median values and low SF-36 physical component summary
(SF-36 PCS) and SF-36 mental component summary (SF-36
MCS) when the values were lower than the median values.
Patients were defined as having poor HRQoL when they
had either low SF-36 PCS or low SF-36 MCS.
2.4. Statistical Analyses. All statistical analyses were con-
ducted using MedCalc statistical software version 19.2 (Med-
Calc Software, Ostend, Belgium). Continuous variables were
expressed as mean with standard deviation, and categorical
variables were expressed as number (percentage). The corre-
lation coefficient between the two variables was obtained
using the Spearman correlation analysis. Significant differ-
ences in categorical variables between the two groups were
analyzed using the chi-squared test and Fisher’s exact test.
Significant differences in continuous variables between the
two groups were compared using Student’s t-test. The
receiver operating characteristic (ROC) curve was used to
identify the optimal cut-off value and the area under the
ROC curve (AUROC) of SAA in differentiating between the
high and low BVAS, as well as poor and high HRQoL. The
multivariable logistic regression analysis which included var-
iables with p values less than 0.05 on the univariable analysis
was conducted to assess the odds ratio (OR) of variables in
predicting high BVAS. The relative risk (RR) was analyzed
using the contingency tables and the chi-squared test. p
values less than 0.05 were considered statistically significant.
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3. Results
3.1. Baseline Data and Association between SAA with AAV-
Specific Variables and Laboratory Data. Among the 75
patients included, MPA (50.7%) was the most common diag-
nosis, followed by GPA and EGPA. The mean age and disease
duration of the patients were 58.9 and 18.2 months, and 26
(34.7%) of the patients were male. The mean value of BVAS,
FFS, VDI, SF-36 PCS score, and SF-36 MCS score was 9.6,
1.3, 3.2, 49.9, and 56.8, respectively. Pulmonary manifesta-
tion (64.0%) was the most common clinical feature present,
and ANCA was detected in 49 (65.3%) of patients (Table 1).
In correlation analysis, SAA was revealed to be positively
correlated with BVAS (r = 0:642) and FFS (r = 0:367) and
was negatively correlated with both the SF-36 PCS
(r = −0:456) and MCS scores (r = −0:394). In addition, SAA
was significantly correlated with white blood cell count, hemo-
globin, platelet count, blood urea nitrogen, creatinine, total
protein, and serum albumin, along with acute phase reactants
of erythrocyte sedimentation rate (ESR) (r = 0:611) and C-
reactive protein (CRP) (r = 0:629). Moreover, although BVAS
was significantly correlated with VDI, SAA was not meaning-
fully correlated with VDI (Table 2).
3.2. Comparison of Clinical and Laboratory Features in
Patients with High and Low BVAS. We divided our patients
into two groups of the high BVAS group (N = 38) and the
low BVAS group (N = 37). There were no differences in
AAV variants between the two groups. However, patients
with high BVAS had shorter disease duration and lower SF-
36 PCS and MCS scores than those with low BVAS. Among
clinical manifestations, patients with high BVAS presented
general, pulmonary, and renal manifestations more fre-
quently than the low BVAS group. Myeloperoxidase-
(MPO-) ANCA and ANCA positivity were detected more
often in patients with high BVAS. In regard to laboratory
data, patients with high BVAS showed higher white blood
cell count, platelet count, blood urea nitrogen, creatinine,
ESR, and CRP but lower hemoglobin, total protein, and
serum albumin compared to patients with low BVAS.
Patients with high BVAS had significantly higher SAA than
the low BVAS group (1317.1 ng/mL vs. 423.1 ng/mL, p <
0:001) (Table 3).
3.3. Comparison of SAA Levels Based on the Presence of Organ
Involvement. We also investigated differences in SAA
depending on the presence or absence of each organ involve-
ment. Patients with general, mucous membrane and eye, pul-
monary, and renal manifestations exhibited higher SAA
levels than those without (Table 4). There was no difference
in SAA levels regarding cutaneous; ear, nose, and throat; car-
diovascular; and nervous system involvement.
3.4. Independent Predictors of High BVAS in Logistic
Regression Analysis. The optimal cut-off of SAA for predict-
ing high BVAS was obtained as 1173.6 ng/mL using the
ROC curve (AUROC 0.782, 95% confidence interval (CI)
0.671-0.869, and p < 0:001) with a sensitivity of 65.8 and
specificity of 94.6 (Figure 1). When we divided AAV patients
into the two groups based on this cut-off of SAA, patients







Age (years) 58:9 ± 15:1
Male gender (N (%)) 26 (34.7%)
Disease duration (months) 18:2 ± 32:2
AAV-specific indices
BVAS 9:6 ± 6:8
FFS (2009) 1:3 ± 0:9
VDI 3:2 ± 1:7
SF-36 PCS score 49:9 ± 23:3
SF-36 MCS score 56:8 ± 21:5
Clinical manifestations (N (%))
General 26 (34.7%)
Cutaneous 9 (12.0%)
Mucous membrane and eye 5 (6.7%)





Nervous system 16 (21.3%)





ANCA positivity 49 (65.3%)
Laboratory data
WBC count (/mm3) 8:9 ± 4:4
Hemoglobin (g/dL) 11:6 ± 2:4
Platelet count (×1000/mm3) 303:3 ± 141:6
Blood urea nitrogen (mg/dL) 24:8 ± 16:7
Creatinine (mg/dL) 1:7 ± 1:8
Total protein (g/dL) 6:3 ± 0:7
Serum albumin (g/dL) 3:6 ± 0:7
AST (IU/L) 20:9 ± 12:8
ALT (IU/L) 24:4 ± 20:9
ESR (mm/hr) 44:6 ± 33:3
CRP (mg/L) 19:4 ± 39:8
SAA (ng/mL) 876:0 ± 825:0
Values are expressed as mean ± standard deviation or number (percentage).
MPA: microscopic polyangiitis; GPA: granulomatosis with polyangiitis;
EGPA: eosinophilic granulomatosis with polyangiitis; AAV: ANCA-
associated vasculitis; ANCA: antineutrophil cytoplasmic antibody; BVAS:
Birmingham Vasculitis Activity Score; FFS: five-factor score; VDI:
vasculitis damage index; SF-36: Short-Form 36-Item Health Survey; PCS:
physical component summary; MCS: mental component summary; P:
perinuclear; C: cytoplasmic; MPO: myeloperoxidase; PR3: proteinase 3;
WBC: white blood cell; AST: aspartate aminotransferase; ALT: alanine
aminotransferase; ESR: erythrocyte sedimentation rate; CRP: C-reactive
protein; SAA: serum amyloid A.
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with SAA > 1173:6 ng/mL exhibited a significantly higher
risk of having high BVAS than those with SAA ≤ 1173:6 ng/
mL (RR 3.419, p < 0:001) (Figure 1).
In the univariable logistic regression analysis, high BVAS
was associated with all laboratory variables included except
P-ANCA. However, in the multivariable logistic regression
analysis, high BVAS was only associated with SAA > 1173:6
ng/mL (OR 15.132, 95% CI 2.656-86.196, and p = 0:002)
and serum albumin (OR 0.132, 95% CI 0.032-0.551, and p
= 0:006) (Table 5).
3.5. Comparison of HRQoL Measures according to SAA
Levels. Next, we compared SAA levels in the patients accord-
ing to measures of HRQoL. SAAwas found to be significantly
higher in patients with low PCS, low MCS, and poor HRQoL
(Figure 2). Similarly, the optimal cut-off of SAA in differenti-
ating poor and high HRQoL was >111.1 ng/mL, with an
AUROC of 0.729 (95% CI 0.614-0.825, p < 0:001) and a sen-
sitivity of 89.1 and specificity of 55.2 (Figure 3). The risk of
having poor HRQoL was also significantly higher in patients
with SAA > 1173:6 ng/mL than in those with SAA ≤ 1173:6
ng/mL (RR 1.493, p = 0:020) (Figure 3).
4. Discussion
In this study, we investigated whether SAA is associated with
the clinical features of AAV and found several interesting
results. First, SAA was well correlated with BVAS, FFS, SF-
36, and acute phase reactants. Second, high BVAS and poor
HRQoL could be predicted by setting an optimal cut-off
value of SAA. Third, SAA > 1173:6 ng/mL was found as an
independent predictor of high BVAS in an adjusted logistic
regression analysis, together with serum albumin. Fourth,
when the patients were classified into two groups according
to the optimal cut-off value of SAA, patients with SAA ≥
1173:6 ng/mL exhibited a significantly higher risk of having
high BVAS and poor HRQoL compared to those without
(RR 3.419 and 1.493). Taken together with these results, we
concluded that SAA could be a useful biomarker in estimat-
ing disease activity and HRQoL in AAV.
We hypothesize that SAA could be relevant to the cross-
sectional disease activity or severity of AAV based on the fact
that SAA could influence neutrophil activation and the pro-
duction of key proinflammatory cytokines implicated in
AAV. First, SAA might enhance the recruitment of neutro-
phils, which are important immune cells in the pathogenesis
of AAV [20]. SAA could bind to formyl peptide receptor 2
(FPR2) on the cell membrane of neutrophils and play as a
chemoattractant driving them to the inflamed tissues [21].
In addition, SAA could bind to FPR2 on the cell membrane
of monocytes and augment the production of C-X-C motif
chemokine ligand 8 (CXCL8). Subsequently, secreted CXCL8
from monocytes could bind to C-X-C motif chemokine
receptor 2 on the cell membrane of neutrophils and also drive
neutrophils to the inflamed tissues in a synergistic way [22].
Second, SAA is capable of forming a vicious cycle of proin-
flammatory cytokine and chemokine production. SAA stim-
ulates various immune cells and tissue-specific cells and
drives them to produce proinflammatory cytokines of IL-
1β, IL-6, and TNF-α [23]. These cytokines, which are also
thought to play an important role in AAV, can increase the
production of SAA from the liver, resulting in continuing a
vicious cycle between SAA and the cytokine/chemokine net-
work [10, 24, 25].
In the present study, we observed that the SAA level was
higher in AAV cases of lung and kidney involvement com-
pared to those without. AAV is a vasculitis mainly affecting
capillaries and adjacent arterioles and venules, and the lungs
and kidneys are organs in which capillaries are predomi-
nantly present in order to exchange air and excrete metabolic
products in the body efficiently. For this reason, the inflam-
matory burden of capillaritis in the lungs and kidneys might
be expected to be much higher than other organs. Therefore,
it may be speculated that compared to other organs, capillar-
itis in the lungs and kidneys provokes a higher amount of the
proinflammatory cytokine, which in turn accelerates the pro-
duction of SAA in the liver, leading to an increase in circulat-
ing concentration of SAA. However, because AAV patients
with mucous membrane and eye involvement had the high-
est level of SAA, the organ-specific relationship between
SAA in AAV should be further investigated.
Since SAA is primarily produced in the liver, SAAmay be
affected by liver diseases in theory [10]. A previous study
reported that SAA-inducing cytokines were upregulated by
hepatitis C virus (HCV) [26]. Thus, it could be speculated
that increased circulating SAA may be influenced by both
the inflammatory burden of AAV and hepatitis. However,
in terms of the correlation between SAA and liver enzymes
Table 2: Correlation of SAA with AAV-specific indices and
laboratory data.




SF-36 PCS score -0.456 <0.001
SF-36 MCS score -0.394 <0.001
WBC count 0.292 0.011
Hemoglobin -0.569 <0.001
Platelet count 0.324 0.005
Blood urea nitrogen 0.350 0.002
Creatinine 0.317 0.006
Total protein -0.292 0.011





SAA: serum amyloid A; AAV: ANCA-associated vasculitis; ANCA:
antineutrophil cytoplasmic antibody; BVAS: Birmingham Vasculitis
Activity Score; FFS: five-factor score; VDI: vasculitis damage index; SF-36:
Short-Form 36-Item Health Survey; PCS: physical component summary;
MCS: mental component summary; WBC: white blood cell; AST: aspartate
aminotransferase; ALT: alanine aminotransferase; ESR: erythrocyte
sedimentation rate; CRP: C-reactive protein.
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Table 3: Comparison of clinical and laboratory features according to BVAS.
Patients with low BVAS (N = 37) Patients with high BVAS (N = 38) p value
Variants (N (%)) 0.264
MPA 16 (43.2%) 22 (57.9%)
GPA 12 (32.4%) 9 (23.7%)
EGPA 9 (24.3%) 7 (18.4%)
Demographic data
Age (years) 59:7 ± 13:2 58:1 ± 16:8 0.644
Male gender (N (%)) 11 (29.7%) 15 (39.5%) 0.379
Disease duration (months) 29:7 ± 37:0 6:9 ± 21:8 0.002
AAV-specific indices
BVAS 4:0 ± 1:9 15:1 ± 5:2 <0.001
FFS (2009) 1:2 ± 0:8 1:4 ± 1:0 0.221
VDI 3:0 ± 1:9 3:4 ± 1:6 0.263
SF-36 PCS score 57:4 ± 23:2 42:6 ± 21:3 0.005
SF-36 MCS score 61:8 ± 20:0 52:0 ± 22:1 0.048
Clinical manifestations (N (%))
General 6 (16.2%) 20 (52.6%) 0.001
Cutaneous 3 (8.1%) 6 (15.8%) 0.480
Mucous membrane and eye 1 (2.7%) 4 (10.5%) 0.358
Ear, nose, and throat 16 (43.2%) 19 (50.0%) 0.560
Pulmonary 19 (51.4%) 29 (76.3%) 0.025
Cardiovascular 2 (5.4%) 3 (7.9%) 0.999
Abdominal 0 (0.0%) 0 (0.0%) N/A
Renal 13 (35.1%) 25 (65.8%) 0.008
Nervous system 8 (21.6%) 8 (21.1%) 0.952
ANCA positivity (N (%))
P-ANCA 16 (43.2%) 25 (65.8%) 0.051
C-ANCA 2 (5.4%) 5 (13.2%) 0.430
MPO-ANCA 13 (35.1%) 24 (63.2%) 0.016
PR3-ANCA 1 (2.7%) 5 (13.2%) 0.200
ANCA positivity 19 (51.4%) 30 (78.9%) 0.013
Laboratory data
WBC count (/mm3) 7:5 ± 3:4 10:4 ± 4:9 0.004
Hemoglobin (g/dL) 12:6 ± 1:8 10:7 ± 2:6 <0.001
Platelet count (×1000/mm3) 256:8 ± 76:7 348:7 ± 173:5 0.004
Blood urea nitrogen (mg/dL) 19:5 ± 10:3 29:9 ± 20:0 0.006
Creatinine (mg/dL) 1:2 ± 1:1 2:3 ± 2:1 0.008
Total protein (g/dL) 6:6 ± 0:6 6:1 ± 0:7 0.004
Serum albumin (g/dL) 4:0 ± 0:4 3:2 ± 0:6 <0.001
AST (IU/L) 21:4 ± 14:0 19:9 ± 8:8 0.609
ALT (IU/L) 23:0 ± 20:2 25:7 ± 21:7 0.578
ESR (mm/hr) 31:4 ± 17:7 57:4 ± 39:6 <0.001
CRP (mg/L) 3:8 ± 6:5 34:5 ± 51:5 <0.001
SAA (ng/mL) 423:1 ± 481:8 1317:1 ± 854:7 <0.001
Values are expressed as mean ± standard deviation or number (percentage). BVAS: Birmingham Vasculitis Activity Score; MPA: microscopic polyangiitis;
GPA: granulomatosis with polyangiitis; EGPA: eosinophilic granulomatosis with polyangiitis; AAV: ANCA-associated vasculitis; ANCA: antineutrophil
cytoplasmic antibody; FFS: five-factor score; VDI: vasculitis damage index; SF-36: Short-Form 36-Item Health Survey; PCS: physical component summary;
MCS: mental component summary; N/A: not applicable; P: perinuclear; C: cytoplasmic; MPO: myeloperoxidase; PR3: proteinase 3; WBC: white blood cell;
AST: aspartate aminotransferase; ALT: alanine aminotransferase; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; SAA: serum amyloid A.
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Table 5: Univariate and multivariate logistic regression analyses for the prediction of high BVAS.
Univariate analysis Multivariate analysis
OR 95% CI p value OR 95% CI p value
P-ANCA 2.524 0.992-6.422 0.052
MPO-ANCA 3.165 1.232-8.130 0.017
ANCA positivity 3.553 1.292-9.772 0.014
WBC count 1.211 1.052-1.393 0.008
Hemoglobin 0.690 0.552-0.862 0.001
Blood urea nitrogen 1.047 1.010-1.085 0.012
Creatinine 1.511 1.083-2.108 0.015
Total protein 0.351 0.162-0.759 0.008
Serum albumin 0.063 0.017-0.239 <0.001 0.132 0.032-0.551 0.006
ESR 1.030 1.011-1.049 0.002
CRP 1.071 1.007-1.138 0.030
SAA > 1173:6 ng/mL 33.654 6.969-162.527 <0.001 15.132 2.656-86.196 0.002
BVAS: Birmingham Vasculitis Activity Score; P: perinuclear; ANCA: antineutrophil cytoplasmic antibody; MPO: myeloperoxidase; WBC: white blood cell;
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Figure 1: Optimal cut-off of SAA in predicting high BVAS and the relative risk according to the cut-off value. The optimal cut-off of SAA for
predicting high BVAS was 1173.6 ng/mL, and patients with SAA > 1173:6 ng/mL exhibited a significantly higher risk of having high BVAS
than those with SAA ≤ 1173:6 ng/mL. SAA: serum amyloid A; BVAS: Birmingham Vasculitis Activity Score; AUROC: area under the
receiver operating characteristic curve; CI: confidence interval; RR: relative risk.
Table 4: Comparison of SAA between patients according to the presence of organ involvement.
Clinical manifestation
SAA (ng/mL) p value
Yes No
General 1425:8 ± 754:5 584:3 ± 708:7 <0.001
Cutaneous 860:1 ± 879:6 878:2 ± 824:4 0.951
Mucous membrane and eye 1948:7 ± 215:6 799:4 ± 798:7 0.002
Ear, nose, and throat 810:9 ± 810:9 933:0 ± 843:3 0.526
Pulmonary 1030:0 ± 859:1 602:3 ± 695:0 0.030
Cardiovascular 896:8 ± 669:7 874:5 ± 839:0 0.954
Renal 1155:0 ± 840:6 589:5 ± 711:7 0.002
Nervous system 562:6 ± 690:9 961:0 ± 842:9 0.087
Values are expressed as mean ± standard deviation. SAA: serum amyloid A.
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of aspartate aminotransferase (AST) and alanine amino-
transferase (ALT), SAA was not significantly correlated with
both AST and ALT. Since there was no significant correlation
between SAA and liver enzymes, and we excluded patients
with chronic hepatitis B virus and HCV infection, it can be
suggested that the elevated SAA level is associated with the
inflammatory burden of AAV in this study.
It is also intriguing that SAA is inversely correlated with
both the physical and mental domains of SF-36, which is a
conventional index to measure HRQoL. In the ROC analysis,
SAA was revealed to be moderately accurate (AUROC 0.7-
0.9) in discriminating poor and high HRQoL as well as in
assessing disease activity [27]. In line with our observation,
it was reported that SAA correlates with HRQoL measures
in systemic sclerosis and could be a predictor of patient-
reported outcome response in patients with rheumatoid
arthritis [28, 29]. However, the HRQoL in patients with
chronic diseases could be influenced by multiple factors such
as disease severity and the use of medications such as gluco-
corticoids [30–32]. Nevertheless, the AUROC of SAA in pre-
dicting poor QoL (AUROC 0.729) was higher than that of
BVAS (AUROC 0.690) and representative acute phase reac-
tants ESR and CRP (AUROC 0.562 and 0.710). In addition,
when we compared SF-36 PCS and MCS scores between cur-
rent steroid users and nonusers to exclude the effect of med-
ications, no difference was observed, implying that SAA
could provide clinically relevant information in assessing
HRQoL in patients with AAV.
This study has a strength; that is, we demonstrated the
predictive potential of SAA for the cross-sectional disease
activity and HRQoL in AAV for the first time. However,
our study also has several limitations. First, the number of
patients included in our study is quite small. Second, the
mechanism by which SAA is associated with the disease
activity of AAV has not been addressed. Third, the results
of the serial SAAmeasurement were not provided. Therefore,
it is necessary to identify the clinical significance of SAA in
AAV through a larger and well-designed study.
5. Conclusion
In conclusion, we showed that SAA was positively correlated
with BVAS and SF-36 scores and significantly increased in
AAV patients with high disease activity and poor HRQoL.
Our results indicate that SAA might be a useful biomarker
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Figure 3: AUROC of SAA in predicting poor HRQoL and relative risk. The AUROC of SAA in predicting poor HRQoL was 0.729, and the
risk of having poor HRQoL was significantly higher in patients with SAA > 1173:6 ng/mL than in those with SAA ≤ 1173:6 ng/mL. AUROC:













































Figure 2: Comparison of SAA levels according to HRQoL measures. Patients with low SF-36 PCS (a), low SF-36 MCS (b), and poor HRQoL
(c) had significantly higher SAA compared to those without. SAA: serum amyloid A; HRQoL: health-related quality-of-life; SF-36: Short-
Form 36-Item Health Survey; PCS: physical component summary; MCS: mental component summary.
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